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Adult T cell Leukemia, an aggressive T-cell malignancy
linked to HTLV-1 infection, is resistant to chemother-
apy. Recently, promising results were obtained with the
combination of arsenic trioxide, interferon alpha and
zidovudine. However, the cellular and molecular
mechanisms of their anti-leukemia activity remain to be
i n v e s t i g a t e d .T ot h a ta i m ,w eh a v er e l i e do nH I S
(Human Immune System) Rag2-/-gc-/- mice. We have
indeed observed that when infected with HTLV-1, these
mice displayed, five months later, an elevated number of
human Tax-expressing T cells in the thymus, the spleen
and the mesenteric lymph nodes. Some of them also
developed T lymphoproliferative diseases.
To determine the effects of these three drugs on the
apparition of these pathological features, Rag2-/-gc-/-
mice were infected with HTLV-1 and, 16 weeks after
infection, daily treated with the drugs for one week and
sacrificed. Untreated HIS mice infected with HTLV-1
were used as control. Treatment resulted in a significant
decrease in the spleen weight as compared to untreated
controls. Interestingly, we also noted a decrease of the
proviral load in thymocytes as well as a drop in the
number of mature activated T cells in the spleen and in
lymph nodes. These data clearly indicate that the HIS
mouse model provides us with the opportunity not only
for the pre-clinical evaluation of therapeutic approaches
against the leukemogenic process associated with
HTLV-1 infection, but also for unraveling the corre-
sponding mechanisms.
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